Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - NewcelX Ltd. (0001783036) (Issuer)
4 - NewcelX Ltd. (0001783036) (Issuer)
ZURICH, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian Patent and Trademark Office has issued Patent Number BR 112018010946-0 covering its innovative cell selection and enrichment technology. The patent protects the manufacturing process of its lead clinical compound, NCEL-101, until November 2036. "The patent grant follows our recently announced successful FDA Type B Pre-IND meeting for NCEL-101, in combination with Eledon’s anti-CD40L monoclonal antibody, tegoprubart, for the treatment of type 1 diabetes, providing a clear regulatory pathwa
The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials Dr. Ricordi to support advancement of NewcelX's Type 1 Diabetes program and strategic collaboration with Eledon Pharmaceuticals ZURICH, July 08, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biotechnology company developing regenerative cell therapies for type 1 diabetes and other serious diseases, today announced the appointment of Camillo Ricordi, M.D., F.N.A.I., to its Scientific Advisory Board. Dr. Ricordi is internationally recognized as one of the world's foremost authorities in diabetes cure-fo
Issued on behalf of Avaí Bio, Inc.As cell-based medicine moves from the lab toward the clinic across diabetes, transplant, and aging, Avaí Bio and partner Austrianova have banked the genetically modified cells that will manufacture their encapsulated alpha-Klotho productLAS VEGAS, July 8, 2026 /CNW/ -- USA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the fast-emerging field of longevity biology, developers are racing to turn engineered and donor-derived cells into durable, manufacturable therapies, and the companies that reach GMP-grade production first are the ones the market takes seriously. That i
4 - NewcelX Ltd. (0001783036) (Issuer)
4 - NewcelX Ltd. (0001783036) (Issuer)
3 - NewcelX Ltd. (0001783036) (Issuer)
The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials Dr. Ricordi to support advancement of NewcelX's Type 1 Diabetes program and strategic collaboration with Eledon Pharmaceuticals ZURICH, July 08, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biotechnology company developing regenerative cell therapies for type 1 diabetes and other serious diseases, today announced the appointment of Camillo Ricordi, M.D., F.N.A.I., to its Scientific Advisory Board. Dr. Ricordi is internationally recognized as one of the world's foremost authorities in diabetes cure-fo
ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB"). Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap ph
ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board ("SAB"). Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and
6-K - NewcelX Ltd. (0001783036) (Filer)
6-K - NewcelX Ltd. (0001783036) (Filer)
6-K - NewcelX Ltd. (0001783036) (Filer)
NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan